Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

McCollough steps down as St Jude group president

This article was originally published in Clinica

Executive Summary

Joseph McCollough has stepped down as group president of St Jude Medical and is retiring from the company. He first joined the firm in 1994 as regional sales director for its cardiac rhythm management (CRM) division – he took on the role of group president in January 2008, overseeing St Jude's US and international divisions and its corporate brand and global marketing functions. Subsequent to his departure, Michael Rousseau, current group president for CRM, will assume responsibility for the US division. Mr Rousseau, who Morgan Stanley analyst David Lewis described as "the natural choice" in succession, had previously ran St Jude's US operations from 2002-08. It is anticipated that his experience could potentially boost the firm's performance in the US, where its CRM and atrial fibrillation franchises have faltered over the last two quarters, noted Mr Lewis. The international division, which is managed by Denis Gestin, will report directly to St Jude president, CEO and chairman Daniel Starks.

You may also be interested in...



Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Roche Dx' EMEA Head To Take Charge After Diggelmann Departs

Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.

Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio

Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT044645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel